IPHA - Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
2025-02-20 11:39:25 ET
Summary
- Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%.
- Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025.
- Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma.
- The global Sezary Syndrome market is expected to reach $2.34 billion by 2037.
Innate Pharma ( IPHA ) had recently received Breakthrough Therapy Designation [BTD] for its anti-KIR3DL2 antibody candidate known as lacutamab. This particular antibody is being developed for the treatment of adult patients with relapsed or refractory Sezary Syndrome [r/r SS]. This program is highly ideal, and the company was already able to report positive results from its open-label phase 2 study using this drug as a monotherapy to treat these patients with r/r SS. Besides the BTD it just received from the FDA today on February 19th 2025, it has already received two other designations from it, which are Fast Track Designation [FTD] from the FDA in 2019 and then PRIME Designation from the European Medicines Agency [EMA] in 2020. Why should investors care about this program now though, with phase 2 data already being reported? That's because the company already noted itself that it is actively seeking a partner in order to advance this program of targeting CTCL patients into a phase 3 study....
Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion